Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects

  • B. M. Bergersen
  • L. Sandvik
  • J. N. Bruun
  • S. Tonstad
Article

Abstract

Highly active antiretroviral therapy (HAART) may induce dyslipidemia and thus increase the risk of future cardiovascular heart disease (CHD). In this cross-sectional study performed in 2000–2001, the prevalence of a Framingham CHD risk score of >20% in HIV-positive individuals treated or not treated with HAART was compared with that in age- and gender-matched controls. The study included 721 subjects: 219 HIV-positive individuals on HAART, 64 HIV-positive, HAART-naïve individuals, and 438 age- and gender-matched controls randomly selected from a simultaneous health survey. The prevalence of a 10-year estimated CHD risk of >20% was 11.9% in patients on HAART compared to 5.3% in controls (P=0.004). The main contributors to the increased CHD risk in patients on HAART were increased prevalence of daily smoking (54.5% vs 30.1%; P<0.001), total cholesterol of >6.2 mmol/l (36.1% vs 21.7%; P<0.001), and HDL cholesterol of < 0.9 mmol/l (20.9% vs 8.0%; P<0.001). In HAART-naïve patients, the prevalence of a 10-year estimated CHD risk of >20% was 6.3% (P=0.25 vs HAART patients, P=0.76 vs controls), the prevalence of daily smoking was 56.3% (P=0.89 vs HAART patients, P<0.001 vs controls), the prevalence of total cholesterol >6.2 mmol/l was 9.4% (P<0.001 vs HAART patients, P=0.019 vs controls), and the prevalence of HDL cholesterol of <0.9 mmol/l was 30.9% (P=0.16 vs HAART patients, P<0.001 vs controls). The results show that, compared to controls, twice as many patients on HAART have an estimated 10-year CHD risk above 20%. These patients are candidates for intensive interventions. HAART patients should be encouraged to permanently stop smoking, make healthy food choices, and increase physical activity. In patients with elevated lipid levels, a change in the HAART regimen or treatment with lipid-lowering drugs should be considered.

References

  1. 1.
    Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F et al (2002) Changes in the cause of death among HIV-positive subjects across Europe: results from the EuroSIDA study. AIDS 16:1663–1671CrossRefPubMedGoogle Scholar
  2. 2.
    Bonnet F, Morlat P, Chene G, Mercie P, Neau D, Chossat I et al (2002) Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998–1999. HIV Med 3:195–199CrossRefPubMedGoogle Scholar
  3. 3.
    Carr A, Miller J, Law M, Cooper DA (2000) A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14:F25–F32CrossRefPubMedGoogle Scholar
  4. 4.
    Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ et al (1999) Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 100:700–705PubMedGoogle Scholar
  5. 5.
    Dube MP, Johnson DL, Currier JS, Leedom JM (1997) Protease inhibitor-associated hyperglycaemia. Lancet 350:713–714Google Scholar
  6. 6.
    Shikuma CM, Waslien C, McKeague J, Baker N, Arakaki M, Cui XW et al (1999) Fasting hyperinsulinemia and increased waist-to-hip ratios in non-wasting individuals with AIDS. AIDS 13:1359–1365CrossRefPubMedGoogle Scholar
  7. 7.
    The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349:1993–2003CrossRefPubMedGoogle Scholar
  8. 8.
    Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D (2003) Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17:2479–2486CrossRefPubMedGoogle Scholar
  9. 9.
    Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC et al (2002) Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360:1747–1748CrossRefPubMedGoogle Scholar
  10. 10.
    Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N et al (2001) Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32:130–139CrossRefPubMedGoogle Scholar
  11. 11.
    Law M, Friis-Møller N, Weber R, Reiss P, Thiebaut R, Kirk O et al (2003) Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med 4:1–10CrossRefGoogle Scholar
  12. 12.
    Saves M, Chene G, Ducimetiere P, Leport C, Le Moal G, Amouyel P et al (2003) Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 37:292–298CrossRefPubMedGoogle Scholar
  13. 13.
    Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN (2003) Prevalence of Hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 22:731–736CrossRefPubMedGoogle Scholar
  14. 14.
    Bergersen BM, Sandvik L, Bruun JN (2004) Body composition changes in 308 Norwegian HIV-positive patients. Scand J Infect Dis 36:186–191CrossRefPubMedGoogle Scholar
  15. 15.
    Sogaard AJ, Selmer R (2004) The Oslo Health Study—objectives, material and methods. http://www.fhi.no/dav/736B5D55E9.rtf
  16. 16.
    Grotvedt L (2002) Health profile for adults in Oslo. Report from The Oslo Health Study 2001-01 (in Norwegian). http://www.fhi.no/davx/tema/helseundersokelse/pdf/hesleprofil_voksne.pdf
  17. 17.
    Norwegian Institute of Public Health (2001) Main questionnaire, Oslo Health Study 2000-01 (HUBRO). http://www.fhi.no/artikler/?id=28243
  18. 18.
    Tverdal A (2001) Significant decline in blood pressure levels after 1996—fact or artefact? Tidsskr Nor Laegeforen 121:1821–1825PubMedGoogle Scholar
  19. 19.
    Anderson KM, Odell PM, Wilson PW, Kannel WB (1991) Cardiovascular disease risk profiles. Am Heart J 121:293–298CrossRefPubMedGoogle Scholar
  20. 20.
    Cybermed (Last revision 04.04.2000) Cardiovascular disease risk profile. http://www.cybermed.jussieu.fr/Scientific/fram.eng.html
  21. 21.
    Tretli S, Lund-Larsen PG, Foss OP (1982) Reliability of questionnaire information on cardiovascular disease and diabetes: cardiovascular disease study in Finnmark County. J Epidemiol Community Health 36:269–273PubMedGoogle Scholar
  22. 22.
    Thomsen TF, McGee D, Davidsen M, Jorgensen T (2002) A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 31:817–822CrossRefPubMedGoogle Scholar
  23. 23.
    Empana JP, Ducimetiere P, Arveiler D, Ferrieres J, Evans A, Ruidavets JB et al (2003) Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J 24:1903–1911CrossRefPubMedGoogle Scholar
  24. 24.
    Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K (1998) Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Blood Press 7:262–269CrossRefPubMedGoogle Scholar
  25. 25.
    Klein D, Hurley LB, Quesenberry CP Jr, Sidney S (2002) Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 30:471–477PubMedGoogle Scholar
  26. 26.
    Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM et al (2000) Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14:51–57CrossRefPubMedGoogle Scholar
  27. 27.
    van der Valk, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A et al (2001) Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 15:2407–2414CrossRefPubMedGoogle Scholar
  28. 28.
    Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A et al (2003) Impact of HIV infection and HAART on serum lipids in men. J Am Med Assoc 289:2978–2982CrossRefGoogle Scholar
  29. 29.
    Friis-Møller N, Sabin CA, Weber R, D’Arminio MA, El Sadr WM, Reiss P et al (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349:1993–2003CrossRefPubMedGoogle Scholar
  30. 30.
    Grundy SM, Denke MA (1990) Dietary influences on serum lipids and lipoproteins. J Lipid Res 31:1149–1172PubMedGoogle Scholar
  31. 31.
    Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG (2001) Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 15:1503–1508CrossRefPubMedGoogle Scholar
  32. 32.
    Barrios A, Blanco F, Garcia-Benayas T, Gomez-Viera JM, de la Cruz JJ, Soriano V et al (2002) Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS 16:2079–2081CrossRefPubMedGoogle Scholar
  33. 33.
    Moreno S, Domingo P, Labarga P, Libre M, Fernandez M, Palacios R et al (2003) Dyslipidemia improvement in patients switching from d4T to tenofovir. 43rd interscience conference on antimicrobial agents and chemotherapy. Abstract no. H-355bGoogle Scholar
  34. 34.
    Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J et al (2001) Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 15:1517–1526CrossRefPubMedGoogle Scholar
  35. 35.
    Sanne I, Piliero P, Squires K, Thiry A, Schnittman S (2003) Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 32:18–29PubMedGoogle Scholar
  36. 36.
    Pecora FP, Kirian MA (2003) Effect of tenofovir on didanosine absorption in patients with HIV. Ann Pharmacother 37:1325–1328CrossRefPubMedGoogle Scholar
  37. 37.
    Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B et al (2001) Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 23:1603–1614CrossRefPubMedGoogle Scholar
  38. 38.
    Kontorinis N, Dieterich DT (2003) Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 23:173–182CrossRefPubMedGoogle Scholar
  39. 39.
    Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG et al (2002) Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an international AIDS society-USA panel. J Acquir Immune Defic Syndr 31:257–275PubMedGoogle Scholar
  40. 40.
    Assmann G, Cullen P, Schulte H (2002) Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105:310–315CrossRefPubMedGoogle Scholar
  41. 41.
    Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D et al (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104:1108–1113PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • B. M. Bergersen
    • 1
  • L. Sandvik
    • 2
  • J. N. Bruun
    • 1
  • S. Tonstad
    • 3
  1. 1.Department of Infectious DiseasesUllevål University HospitalOsloNorway
  2. 2.Centre for Clinical ResearchUllevål University HospitalOsloNorway
  3. 3.Department of Preventive CardiologyUllevål University HospitalOsloNorway

Personalised recommendations